Novel Cancer Treatment Using Oncolytic Virus Therapy
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/978-3-030-80962-1_251-1
Reference74 articles.
1. Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D (2018) The advent of oncolytic virotherapy in oncology: the Rigvir® story. Eur J Pharmacol 837:117–126. https://doi.org/10.1016/J.EJPHAR.2018.08.042
2. Almutairi AR, Alkhatib NS, Oh M et al (2019) Economic evaluation of Talimogene Laherparepvec plus Ipilimumab combination therapy vs Ipilimumab monotherapy in patients with advanced Unresectable melanoma. JAMA Dermatol 155(1):22–28. https://doi.org/10.1001/JAMADERMATOL.2018.3958
3. Andtbacka RHI, Kaufman HL, Collichio F et al (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. https://doi.org/10.1200/JCO.2014.58.3377
4. Andtbacka RHI, Agarwala SS, Ollila DW et al (2016) Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck 38(12):1752–1758. https://doi.org/10.1002/HED.24522
5. Andtbacka RHI, Collichio F, Harrington KJ et al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7(1):1–11. https://doi.org/10.1186/S40425-019-0623-Z/FIGURES/3
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3